Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page’s UI/build “Revision” marker was updated from v3.5.2 to v3.5.3. This reflects a platform version change rather than an update to the trial details.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision: v3.5.2 is now displayed, replacing Revision: v3.5.0. This appears to be an internal version update with no changes to the study content.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded revision note v3.5.0 and removed revision note v3.4.3.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated to v3.4.3; the prior revision v3.4.2 is superseded. This appears to be a metadata update with no changes to the study details.SummaryDifference0.1%

- Check87 days agoChange DetectedAddition of Revision: v3.4.2 and deletion of notices about government funding lapse and prior Revision: v3.4.1. These updates are administrative in nature and do not modify study data or core page content.SummaryDifference0.5%

- Check94 days agoChange DetectedAdded a government funding status banner noting possible delays and open status, and updated the site version to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.